The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
Non-hodgkin Lymphoma, Hodgkin Lymphoma
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
-
University of Alabama, Birmingham, Alabama, United States, 35233
University of Flordia, Gainesville, Florida, United States, 32610
New York Medical College, Valhalla, New York, United States, 10595
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
3 Years to 39 Years
ALL
No
New York Medical College,
Mitchell Cairo, MD, PRINCIPAL_INVESTIGATOR, New York Medical Center
2028-06-30